We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why Investors Should Hold AngioDynamics Stock Now
Read MoreHide Full Article
AngioDynamics Inc. (ANGO - Free Report) is gaining prominence in the MedTech space, courtesy of its flagship platform — the NanoKnife System. Also, it has a market capitalization of approximately $768.8 million. However, the company is witnessing temporary sluggishness in the Venous Insufficiency business and PICC product lines.
In a year’s time, this Zacks Rank #3 (Hold) stock has gained 21.3% compared with the industry’s 17.3% rally.
Here we take a quick look at AngioDynamics’ major headwinds and discuss the factors that ensure near-term recovery.
What’s Deterring the Stock?
AngioDynamics’ weak Venous Insufficiency business and decline in PICC product lines negatively impacted its performance in the fiscal first quarter. Additionally, the company’s U.S. sales took a hit in the quarter. In fact, management expects sluggish growth at Venous Insufficiency business to persist in the fiscal second quarter as well.
Why Should You Still Retain the Stock?
AngioDynamics’ NanoKnife system is acting as a key catalyst to its Oncology business. The product has previously received FDA clearance for the surgical ablation of the soft tissue.
Currently, the company is experiencing solid demand for its coveted NanoKnife system to treat tumors. AngioDynamics is already looking to further broaden its commercial opportunities. Apart from Germany and Denmark, the company is looking forward to achieve the same in Europe and the United Kingdom.
In the first quarter of fiscal 2019, NanoKnife revenues grew 7% year over year on increasing global adoption of the technology.
Solid Estimate Revisions
The Zacks Consensus Estimate for fiscal second-quarter earnings is pegged at 21 cents, up 31.3% year over year. The consensus mark for the revenues stands at $88.9 million, reflecting a 2.5% increase year over year.
For fiscal 2019, the Zacks Consensus Estimate for revenues is pegged at $357.1 million, mirroring an increase of 3.7%. For adjusted earnings, the same is pinned at 85 cents, up 14.9% year over year.
A few better-ranked stocks in the broader medical space are Quidel Corporation (QDEL - Free Report) , STAAR Surgical Company (STAA - Free Report) and Illumina, Inc. (ILMN - Free Report) .
With a Zacks Rank #1, STAAR Surgical delivered average four-quarter positive earnings surprise of 400%.
Illumina’s long-term earnings growth rate is projected at 23.4%. The stock carries a Zacks Rank #2 (Buy).
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Here's Why Investors Should Hold AngioDynamics Stock Now
AngioDynamics Inc. (ANGO - Free Report) is gaining prominence in the MedTech space, courtesy of its flagship platform — the NanoKnife System. Also, it has a market capitalization of approximately $768.8 million. However, the company is witnessing temporary sluggishness in the Venous Insufficiency business and PICC product lines.
In a year’s time, this Zacks Rank #3 (Hold) stock has gained 21.3% compared with the industry’s 17.3% rally.
Here we take a quick look at AngioDynamics’ major headwinds and discuss the factors that ensure near-term recovery.
What’s Deterring the Stock?
AngioDynamics’ weak Venous Insufficiency business and decline in PICC product lines negatively impacted its performance in the fiscal first quarter. Additionally, the company’s U.S. sales took a hit in the quarter. In fact, management expects sluggish growth at Venous Insufficiency business to persist in the fiscal second quarter as well.
Why Should You Still Retain the Stock?
AngioDynamics’ NanoKnife system is acting as a key catalyst to its Oncology business. The product has previously received FDA clearance for the surgical ablation of the soft tissue.
Currently, the company is experiencing solid demand for its coveted NanoKnife system to treat tumors. AngioDynamics is already looking to further broaden its commercial opportunities. Apart from Germany and Denmark, the company is looking forward to achieve the same in Europe and the United Kingdom.
In the first quarter of fiscal 2019, NanoKnife revenues grew 7% year over year on increasing global adoption of the technology.
Solid Estimate Revisions
The Zacks Consensus Estimate for fiscal second-quarter earnings is pegged at 21 cents, up 31.3% year over year. The consensus mark for the revenues stands at $88.9 million, reflecting a 2.5% increase year over year.
For fiscal 2019, the Zacks Consensus Estimate for revenues is pegged at $357.1 million, mirroring an increase of 3.7%. For adjusted earnings, the same is pinned at 85 cents, up 14.9% year over year.
AngioDynamics, Inc. Price and Consensus
AngioDynamics, Inc. Price and Consensus | AngioDynamics, Inc. Quote
Stocks to Consider
A few better-ranked stocks in the broader medical space are Quidel Corporation (QDEL - Free Report) , STAAR Surgical Company (STAA - Free Report) and Illumina, Inc. (ILMN - Free Report) .
Quidel Corporation has long-term expected earnings growth rate of 25% and a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
With a Zacks Rank #1, STAAR Surgical delivered average four-quarter positive earnings surprise of 400%.
Illumina’s long-term earnings growth rate is projected at 23.4%. The stock carries a Zacks Rank #2 (Buy).
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>